Author | Daniel R. Carrizosa, MD, MS

Articles

New Targets and New Mechanisms in Lung Cancer

May 15, 2013

This review will describe the well-known use of VEGF antibodies; the current uses of EGFR and ALK tyrosine kinase inhibitors; newer agents being used against MET, FGFR, and other intracellular targets; insights regarding the field of immunotherapy in lung cancer; and finally, newer developments in chemotherapy.